二米瑞通过SNHG17/Mir-34a/SIDT2轴影响自,改善心肌功能
Hai Xiao1,2, Yan Xiao2,3, Xueliang Zeng4
1Department of Pathology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Current molecular pharmacology
|February 20, 2025
概括
二米瑞 (DHM) 通过调节SNHG17/miR-34a/SIDT2通路,改善糖尿病心肌病 (DCM) 的心脏功能. 这减少了炎症,纤维化和自问题,为DCM提供了潜在的治疗益处.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病心肌病 (DCM) 是糖尿病 (DM) 的严重并发症.
- 作为一种黄类药物,二胺 (DHM) 显示出潜在的心脏保护作用.
- 糖尿病引起的心肌损伤和自的DHM的确切机制尚不清楚.
研究的目的:
- 调查DHM对心脏功能和DCM病理学的影响.
- 阐明SNHG17/miR-34a/SIDT2通路在DHM作用中的作用.
- 了解DHM对糖尿病心脏自的影响.
主要方法:
- 在体内研究中,使用DM小鼠模型治疗DHM,通过马森纤维化染色进行评估.
- 在高葡萄糖诱导的HL-1细胞的体外研究,使用MTT测定可活性和流细胞计测定可亡.
- 生物化学分析包括对心脏酶/炎症的酶关联免疫吸收测定和蛋白质水平的西方斑点 (AMPK/mTOR,自标志物).
主要成果:
- 在DM小鼠中,DHM治疗改善了心脏功能,并减少了心脏损伤标志物.
- DHM减轻了心肌纤维化,炎症和自失调.
- DHM上调了SNHG17,降低了miR-34a,并恢复了SIDT2介导的自平衡,缓解了亡和纤维化.
结论:
- 通过向SNHG17/miR-34a/SIDT2轴,DHM增强心脏功能,并与DCM进展作斗争.
- 这种机制涉及减少炎症,纤维化和自失衡.
- DHM显示出作为糖尿病心肌病治疗剂的潜力.
相关概念视频
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...